Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 08:30 ET | Source: NurExone Biologic Inc

NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model

TORONTO and HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) a biopharmaceutical company developing...
January 21, 2025 16:20 ET | Source: NurExone Biologic Inc

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director

NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
March 27, 2024 17:05 ET | Source: NurExone Biologic Inc

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise